Samuel Agresta - 07 Aug 2026 Form 4 Insider Report for OnKure Therapeutics, Inc. (OKUR)

Reporting relationship: Chief Medical Officer
Issuer ticker: OKUR
Reported as of: 07 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Aug 2026, 16:23:28 UTC
Prior SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Rogan Nunn, by power of attorney

Key filing fact

Samuel Agresta filed Form 4 for OnKure Therapeutics, Inc. (OKUR) on 11 Aug 2026.

Key facts

This page summarizes Samuel Agresta's Form 4 filing for OnKure Therapeutics, Inc. (OKUR).
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 11 Aug 2026, 16:23.

Change

Previous filing in this sequence was filed on 03 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001748961 Primary reporting owner

Agresta Samuel

Relationship: Chief Medical Officer
Address: C/O ONKURE THERAPEUTICS, INC., 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Signature: /s/ Rogan Nunn, by power of attorney
Signature date: 11 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OKUR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 50,000
Exercise price: $4.14
Footnotes: F1

OKUR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -18,588
Change %: -100%
Price
Shares after: 0
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 18,588
Exercise price: $13.99
Footnotes: F2, F3, F4

OKUR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +18,588
Change %
Price
Shares after: 18,588
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 18,588
Exercise price: $4.14
Footnotes: F2, F3, F4

OKUR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -131,396
Change %: -100%
Price
Shares after: 0
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 131,396
Exercise price: $18.20
Footnotes: F3, F4, F5

OKUR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +131,396
Change %
Price
Shares after: 131,396
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 131,396
Exercise price: $4.14
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Footnote F2

1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Footnote F3

The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

Footnote F4

Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

Footnote F5

1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.